SCM
RARE icon

Segantii Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Segantii Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-200
Closed -$14K – 214
2017
Q1 		$14K Buy
+200
New +$15.2K ﹤0.01% 363

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Segantii Capital Management's RARE Position: Q2 2017 in Review

Segantii Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2017, closing a stake of 200 shares — an estimated $14K sold.

Segantii Capital Management first reported a position in RARE in Q1 2017 and held it in 1 quarter. The position peaked at $14K in Q1 2017. 158 funds tracked by Wall St. Rank hold RARE as of Q2 2017.

  • Segantii Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 200 Ultragenyx Pharmaceutical shares in Q2 2017, an estimated $14K.
  • Segantii Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2017 and held it in 1 quarter.
  • Segantii Capital Management's Ultragenyx Pharmaceutical position peaked at $14K in Q1 2017.
  • 158 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.